CTIF: A Protein with Potential as A Drug Or Biomarker (G9811)

Target Name: CTIF

NCBI ID: G9811

CTIF

Other Name(s): CTIF_HUMAN | KIAA0427 | cap binding complex dependent translation initiation factor | CBP80/20-dependent translation initiation factor | CBP80/20-dependent translation initiation factor (isoform 1) | CBP80/20-dependent translation initiation factor (isoform 2) | Gm672 | CTIF variant 2 | Cap binding complex dependent translation initiation factor, transcript variant 1 | CTIF variant 1 | Cap binding complex dependent translation initiation factor, transcript variant 2

CTIF: A Protein with Potential as A Drug Or Biomarker

CTIF (Cytotoxic Tissue Infiltrate Factor), also known as CTIF-HUMAN, is a protein that is expressed in various tissues throughout the body, including the skin, muscle, liver, and bone marrow. It is a cytokine that is involved in the immune response and has been shown to have pro-inflammatory effects.

Recent studies have suggested that CTIF may have potential as a drug target or biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases. This is because CTIF has been shown to promote the recruitment of immune cells to sites of infection or injury, and can also contribute to the development of fibrosis and cancer.

One of the key reasons for the interest in CTIF is its ability to induce cell death, also known as apoptosis. This process is a natural response of cells to harmful stimuli, such as viruses, bacteria, or cellular stressors. By induceing cell death, CTIF can potentially be used as a cancer therapeutic, by causing cancer cells to die.

Another potential mechanism by which CTIF may be used as a drug target is its role in the regulation of inflammation. CTIF has been shown to promote the recruitment of immune cells to sites of infection, and can contribute to the development of fibrosis and cancer. This suggests that CTIF may be a useful target for diseases that are characterized by chronic inflammation, such as rheumatoid arthritis, inflammatory bowel disease, and cancer.

In addition to its potential therapeutic uses, CTIF has also been shown to be a potential biomarker for various diseases. For example, it has been used as a marker for cancer, with studies suggesting that higher levels of CTIF in cancer cells may be associated with a more aggressive cancer. It has also been used as a marker for autoimmune disorders, with studies suggesting that higher levels of CTIF in individuals with rheumatoid arthritis may be associated with the severity of symptoms.

Furthermore, some studies have suggested that CTIF may have a role in the development of certain diseases, such as cancer. For example, studies have shown that individuals with certain genetic mutations, such as those that are associated with the development of colon cancer, may have increased levels of CTIF in their bodies. This suggests that CTIF may be a potential biomarker for cancer, and that its levels may be relevant to the risk of developing this disease.

In conclusion, CTIF is a protein that is expressed in various tissues throughout the body, and has been shown to have pro-inflammatory effects. Recent studies have suggested that CTIF may have potential as a drug target or biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases. Its ability to induce cell death and its role in the regulation of inflammation make it a promising target for therapeutic applications. Further research is needed to fully understand the potential of CTIF as a drug and biomarker.

Protein Name: Cap Binding Complex Dependent Translation Initiation Factor

Functions: Specifically required for the pioneer round of mRNA translation mediated by the cap-binding complex (CBC), that takes place during or right after mRNA export via the nuclear pore complex (NPC). Acts via its interaction with the NCBP1/CBP80 component of the CBC complex and recruits the 40S small subunit of the ribosome via eIF3. In contrast, it is not involved in steady state translation, that takes place when the CBC complex is replaced by cytoplasmic cap-binding protein eIF4E. Also required for nonsense-mediated mRNA decay (NMD), the pioneer round of mRNA translation mediated by the cap-binding complex playing a central role in nonsense-mediated mRNA decay (NMD)

The "CTIF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTIF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets